HLA-DQ polymorphism influences progression of demyelination and neurologic deficits in a viral model of multiple sclerosis.
The importance of genetic susceptibility in determining the progression of demyelination and neurologic deficits is a major focus in neuroscience. We studied the influence of human leukocyte antigen (HLA)-DQ polymorphisms on disease course and neurologic impairment in virus-induced demyelination. HLA-DQ6 or DQ8 was inserted as a transgene into mice lacking endogenous expression of MHC class I (beta(2)m) and class II (H2-A(beta)) molecules. Following Theiler's murine encephalomyelitis virus (TMEV) infection, we assessed survival, virus persistence, demyelination, and clinical disease. Mice lacking expression of endogenous class I and class II molecules (beta(2)m(o) Abeta(o) mice) died 3 to 4 weeks postinfection (p.i.) due to overwhelming virus replication in neurons. beta(2)m(o) Abeta(o) DQ6 and beta(2)m(o) Abeta(o) DQ8 mice had increased survival and decreased gray matter disease and virus replication compared to nontransgenic littermate controls. Both beta(2)m(o) Abeta(o) DQ6 and beta(2)m(o) Abeta(o) DQ8 mice developed chronic virus persistence in glial cells of the white matter of the spinal cord, with greater numbers of virus antigen-positive cells in beta(2)m(o) Abeta(o) DQ8 than in beta(2)m(o) Abeta(o) DQ6 mice. At day 45 p.i., the demyelinating lesions in the spinal cord of beta(2)m(o) Abeta(o) DQ8 were larger than those in the beta(2)m(o) Abeta(o) DQ6 mice. Earlier and more profound neurologic deficits were observed in beta(2)m(o) Abeta (o) DQ8 mice compared to beta(2)m(o) Abeta(o) DQ6 mice, although by 120 days p.i. both strains of mice showed similar extent of demyelination and neurologic deficits. Delayed-type hypersensitivity and antibody responses to TMEV demonstrated that the mice mounted class II-mediated cellular and humoral immune responses. The results are consistent with the hypothesis that rates of progression of demyelination and neurologic deficits are related to the differential ability of DQ6 and DQ8 transgenes to modulate the immune response and control virus.
Pavelko
K D
KD
Department of Immunology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905, USA.
Drescher
K M
KM
McGavern
D B
DB
David
C S
CS
Rodriguez
M
M
D000208:Acute Disease; D000818:Animals; D000917:Antibody Formation / Q000235:genetics; D000956:Antigens, Viral / Q000032:analysis; D001921:Brain / Q000276:immunology / Q000821:virology; D018188:Cardiovirus Infections / Q000235:genetics* / Q000276:immunology / Q000401:mortality; D002908:Chronic Disease; D003711:Demyelinating Diseases / Q000235:genetics / Q000276:immunology; D004195:Disease Models, Animal; D018450:Disease Progression; D020022:Genetic Predisposition to Disease; D006683:HLA-DQ Antigens / Q000235:genetics*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology / Q000821:virology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009043:Motor Activity; D009103:Multiple Sclerosis / Q000235:genetics* / Q000276:immunology; D009412:Nerve Fibers / Q000276:immunology / Q000821:virology; D011110:Polymorphism, Genetic; D004856:Postural Balance; D013116:Spinal Cord / Q000276:immunology / Q000821:virology; D016019:Survival Analysis; D017945:Theilovirus; D014779:Virus Replication / Q000276:immunology
D000956:Antigens, Viral; D006683:HLA-DQ Antigens